Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
The IPO market stayed relatively quiet, with only one IPO and one SPAC pricing this past week. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. AN2 Therapeutics (ANTX) priced its...read more
AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, raised $69 million by offering 4.6 million shares at $15, the midpoint of the $14 to $16 range. The company offered 0.6 million (15%) more shares than anticipated...read more
AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16....read more
Biotech IPOs struggle to tread water amid challenging market conditions
Despite weak trading in the biotech sector, another drug developer is preparing to take on a challenging IPO market. Norovirus vaccine developer HilleVax (HLVX) plans to raise $175 million this week in the first major biotech IPO of the 2Q. ...read more
US IPO Weekly Recap: The IPO market remains frozen in a 1 IPO week
The IPO market stayed relatively quiet, with only one IPO and one SPAC pricing this past week. Pipeline activity maintained its slow pace, with only two small IPOs and one SPAC submitting initial filings. AN2 Therapeutics (ANTX) priced its...read more
Lung disease biotech AN2 Therapeutics prices upsized IPO at $15 midpoint
AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, raised $69 million by offering 4.6 million shares at $15, the midpoint of the $14 to $16 range. The company offered 0.6 million (15%) more shares than anticipated...read more
Lung disease biotech AN2 Therapeutics sets terms for $60 million IPO
AN2 Therapeutics, a Phase 2/3-ready biotech developing an in-licensed therapy for NTM lung disease, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16....read more